Antigen-Specific CD8⁺ T Cell based Artificial T Cell Stimulator Development Service

The Importance of Antigen-Specific CD8+ T Cell-based Artificial T Cell Stimulator Development

Adoptive immunotherapy utilizing antigen (Ag)-specific cytotoxic T lymphocytes (CTLs) holds promise for treating infectious diseases and cancer. However, generating sufficient numbers of these cells for effective therapy remains a challenge. Cell-based artificial T cell stimulators offer a promising solution. These engineered cells can effectively activate, expand, and differentiate Ag-specific CD8+ T cells into potent effector cells, overcoming limitations associated with traditional methods. This approach provides a more reproducible and potentially more cost-effective strategy for generating therapeutic quantities of Ag-specific CTLs for adoptive immunotherapy.

Fig.1 In vitro expansion of T cells stimulated by APCs or artificial T cell stimulators.¹

Antigen-Specific CD8⁺ T Cell based Artificial T Cell Stimulator Development Service at Creative Biolabs

Creative Biolabs provides a specialized service for developing antigen-specific CD8⁺ T cell-based artificial T cell stimulators. We engineer cell lines to mimic natural APCs, enabling them to present antigens via HLA class I, deliver co-stimulatory signals, and produce cytokines that effectively activate and expand antigen-specific CD8+ T cells. This approach allows for the generation of potent T cell responses against various threats, including viral infections and cancer. Depending on the properties that customers want to impart to the expanded CD8+ T cells, we provide customized services to express specific signaling proteins in the artificial T cell stimulators.

In addition, we maintain rigorous quality control throughout the artificial T cell stimulator development process, ensuring cell line characterization, HLA-peptide loading verification, and functional assessment of artificial T cell stimulator-mediated CD8+ T cell activation. Furthermore, we also supply additional services to perform comprehensive functional assays on expanded CD8+ T cells, including cytotoxicity assays, cytokine secretion assays, and proliferation assays, to evaluate their quality and potency. At Creative Biolabs, we prioritize efficient project management with clear timelines and regular communication, offering flexible collaboration options to meet the specific needs and timelines of each project.

Service Highlights

• Advanced genetic engineering technologies assistance.
• Customized development to satisfy customers' various demands.
• The highest industry regulatory standards complied development process.
• Competent research team.
• Efficient project management.

Associated Services

In addition to our specialized services for developing antigen-specific CD8+ T cell-based artificial T cell stimulators, Creative Biolabs also offers a comprehensive range of customized artificial T cell stimulator development services for other immune cell subsets, including but not limited to CD4+ T cells, and NK cells. This expanded portfolio allows us to address a wider spectrum of immunological research and therapeutic applications.

• Antigen-Specific CD4+ T Cell based Artificial T Cell Stimulator Development Service
• Polyclonal CD3+ T Cell based Artificial T Cell Stimulator Development Service
• Chimeric Antigen Receptor Transduced T Cell based Artificial T Cell Stimulator Development Service
• Invariant Natural Killer T Cell based Artificial T Cell Stimulator Development Service
• Natural Killer Cell based Artificial T Cell Stimulator Development Service

Creative Biolabs excels at offering customized development services for antigen-specific CD8+ T cells, whether you want to build an artificial T cell stimulator to expand, enrich, and lengthen the lifespan of antigen-specific CD8+ T cells or endow antigen-specific CD8+ T cells with additional capabilities. Please contact us to learn more about our comprehensive suite of antigen-specific CD8+ T cell based artificial T cell stimulator development services.

Reference

1. Katiyar, Vatsala, Jason Chesney, and Goetz Kloecker. "Cellular therapy for lung cancer: focusing on Chimeric Antigen Receptor T (CAR T) cells and Tumor-Infiltrating Lymphocyte (TIL) therapy." Cancers 15.14 (2023): 3733. Distributed under Open Access License CC BY 4.0, without modification.